INTERNATIONAL BIOTECHNOLOGY TRUST PLC (the Company)
Portfolio Update as at 31 July 2017
Net Assets |
£244m |
Net Assets per share |
650p |
Share price |
624p |
Total value of unquoted investments |
£22m |
Total number of portfolio companies |
91 |
Dividend |
4% of NAV per annum |
Top Ten Quoted Investments
Company Name |
% NAV |
Celgene |
7.6 |
Regeneron |
6.6 |
Biogen |
5.4 |
Genmab |
5.0 |
Vertex |
4.3 |
Gilead |
3.9 |
Alexion |
3.7 |
Biomarin |
3.2 |
Incyte |
3.2 |
Amgen |
2.8 |
|
----------- |
Total |
45.7 |
Geographical Allocation |
% NAV |
US & Canada |
83 |
Europe & UK |
17 |
|
----------- |
Total |
100 |
Quoted/Unquoted Allocation |
% NAV |
Quoted |
91 |
Unquoted |
9 |
|
----------- |
Total |
100 |
NAV % Market Cap |
% NAV |
Large Cap >USD10BN |
50 |
Mid Cap =USD1-10BN |
27 |
Small Cap <USD1BN |
23 |
|
----------- |
Total |
100 |
NAV % by Therapeutic Areas |
% NAV |
Oncology |
37 |
Rare diseases |
14 |
Ophthalmology |
9 |
CNS |
9 |
Inflammation |
6 |
Medtech |
2 |
Other |
23 |
|
----------- |
Total |
100 |
BNP Paribas Secretarial Services Limited
Company Secretary
23 AUGUST 2017